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culture-positive endocarditis. In-hospital clinical course, the need for surgery
and mortality are similar to those in patients with blood culture-positive endo-
carditis.
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Embolic complications (EC) occur in about 30% to 40% of left-sided
infective endocarditis (LSIE) and are associated with a poor prognosis. We
analysed risk factors for embolic events in the systematic analysis of a large
cohort of consecutive patients treated for infective endocarditis (IE).
Methods: 533 consecutive patients admitted for definite or probable LSIE
were included in this study.
Results: Mean age was 64 and 26% had a prosthetic valve. The loca-
tion of IE was aortic in 68%. Causative microorganisms were Streptococ-
caceae in 40% and Staphylococcaceae in 27%. Rate of valve surgery and
mortality during the initial hospital stay were 26% and 11%, respectively.
The mean follow up was 5±6 years. Embolic events occur in 164 patients
(30%). In multivariate analysis, presence of vegetation was an independent
risk factor for embolic event (hazard ratio HR=1.96, p<0.001), whilst older
age and Streptococcus infection were independently associated with a
lower risk of embolic events (HR=0.99, p=0.02 and HR=0.64, p=0.02
respectively). 
Conclusions: Patients with LSIE and streptococcal infection have a lower
risk of embolic events than others. The presence of vegetations was indepen-
dently associated with an increased risk of embolic events. 
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Background: The PROTECT AF trial previously demonstrated that left
atrial appendage closure (LAAC) was non inferior to warfarin in patients with
nonvalvular atrial fibrillation (NVAF). However, this trial included patients
eligible for anticoagulation therapy who received warfarin for 6 weeks after
device implantation. The purpose of the present study was to assess the safety
and efficacy of LAAC for stroke patients with NVAF and contraindication for
anticoagulation. 
Methods: Consecutive patients with a previous ischemic or hemor-
rhagic stroke, NVAF and contraindication for anticoagulation underwent
LAAC with the Amplatzer Cardiac Plug device between July 2010 and
July 2013 in a French university hospital. Follow-up included clinical
evaluation at 3 and 12 months, and a cardiac computed tomography (CT)
at 3 months. Single-antiplatelet therapy was prescribed after the procedure
for a minimum of 3 months and stopped if the control cardiac CT demon-
strated complete LAA exclusion. RESULTS: 26 patients (age 73±8 years)
were included. The mean CHA2DS2-VASc and HAS-BLED scores were
4±1.5 and 4±0.8, respectively. The main contraindications for anticoagula-
tion were: intracerebral hemorrhage while receiving anticoagulation
(62%), ischemic stroke with large hemorrhagic transformation (15%) and
probable cerebral amyloid angiopathy (8%). The procedure was successful
in 100%. Procedure-related complications were serious pericardial effu-
sion (3.8%) and femoral bleeding (7.7%). During a mean follow-up of 8.6
(3-16) months, ischemic stroke occurred in 2 patients (7.7%), after anti-
platelet therapy was stopped for one of them. One patient died of an intra-
cranial hemorrhage. 
Conclusion: LAAC followed by a single antiplatelet therapy could be a
reasonable alternative for stroke patients with NVAF and contraindication for
anticoagulation. Lifelong rather than short-term single antiplatelet therapy
should be prescribed after the procedure for patients at high cardio-vascular
risk.
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Background: Behcet's disease is a multisystem disorder and classified as
« vasculitic syndrome with a wide variety of clinical manifestations. » Cardiac
involvement is very rare but can occur with different presentations.
Objective: To analyze the clinical characteristics of Behcet's disease with
cardiac involvement.
Methods: Patients diagnosed as Behcet's disease with cardiac involvement
in our Hospital from 1998 to 2013 were included in this analysis. The clinical
characteristics of these patients were studied retrospectively.
Results: Eighteen cardiac manifestations observed in 13 patients with
Behçet's disease are reported. 11 (84.6%) patients were male, with a mean
(±SD) age at BD diagnosis of 34.2±9.9 years. Cardiac involvement was the
first feature of BD in 9 (69.23%) patients. Cardiac involvement included ST-
elevation myocardial infarction (4 cases, 22.22%), stable angina (1case,
5.5%), right heart failure (2 cases 11.1%), pericardial effusion (4 cases,
22.22%), intracardiac thrombus (2 cases, 11.1%), pulmonary artery hyperten-
sion (4 cases, 22.22%) (Consecutive to pulmonary embolism in three cases)
and valvular disease (mitral insufficiency) (1 case, 5.5%). After a median
follow-up of 59.73 (0-180) months, 2 patients had died (directly related to car-
diac involvement).
Conclusions: The manifestation of cardiac involvement in Behcet's disease
is various. The involvement of pulmonary artery is an independent correlative
factor of mortality. Cardiologists should always bear in mind potential threats
of (a) symptomatic cardiovascular involvement in BD. 
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No definitive recommendation is available concerning optimal anti-
thrombotic therapy in pregnant women with a mechanical heart valve. The
purpose of the current study was to evaluate the clinical results of Enoxa-
parin treatment with respect to pregnancy outcome and maternal compli-
cations. 
From 2003 to 2012, 50 pregnancies were reviewed in 42 women. The
valve replaced was mitral (n=28), aortic (n=4), and both (n=10). Enoxaparin
(100 U/kg, twice daily) was used in 25 pregnancies between 6 and 12 weeks
of gestation and close-to-term only, and coumarin derivatives were used at
other times. 25 pregnant women treated with coumarin derivatives throughout
pregnancy were compared to evaluate the safety and efficacy of Enoxaparin. 
4 mothers developed mitral valve thrombosis (2 were on LMWH and 4 on
coumarin). Hemorrhagic complications occurred in 5 patients, 2 of whom
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required transfusion. There was 1 maternal death from valve thrombosis (in
the Enoxaparin-treated group). The incidence of maternal complications was
similar between the 2 groups. 2 cases ended in early miscarriage, and 5 cases
ended in intrauterine fetal death. The frequencies of fetal complications, live
born and healthy babies were similar between the 2 groups.
Regarding the efficacy and safety of antithrombotic treatment in preg-
nant women with prosthetic heart valves, Enoxaparin treatment during the
first trimester is an acceptable regimen. These patients require close sur-
veillance for bleeding and thrombotic complications within a multidisci-
plinary setting
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Background: mitral stenosis is characterized by pathological remodelling
of valvular tissue but the molecular effectors involved in these processes are
not well known. The role of matrix metalloproteinase MMP-9, MMP-3, and
tissue inhibitor of matrix metalloproteinase (TIMP)-1 and TIMP-2 are investi-
gated here.
Subjects and methods: 235 patients with mitral stenosis and 150 healthy
control subjects were recruited. MMP-9, MMP-3, TIMP-1 and TIMP-2 levels
in plasma were measured using an ELISA assay. 
Results: The plasma concentrations of MMP-3, TIMP-1 were signifi-
cantly lower in patients compared with control group. MMP-9 rate is sig-
nificantly increased in patients with mitral stenosis. In men, a negative
correlation was observed between calcification degree and rate of MMP-9
(r=–0.484, p<0.001) and positive with MMP-3 (r=0.588, p<0.001). In
women, positive correlation was found between MMP-9 and mitral area
(r=0.387, p=0.002) and also between MMP3 and calcification degree
(r=0.603, p<0.001). 
Conclusion: This study demonstrates the involvement of the MMP/TIMP
system in ECM remodelling of stenosis mitral. We have shown a difference in
level of MMP- 9 between the mitral stenosis and the control. MMP9 was
involved in calcification of the mitrale valve. 
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Background: the diagnosis of infected protheses in patients with long
standing fever is difficult, challenging and has major impact on the manage-
ment. 
Aim: Since 18-Fluo Desoxyglucose positron emission tomography per-
formed together with computerized tomography (FDG PET-CT) has a role in
the diagnosis and localization of infection; we evaluated its value in the diag-
nosis of infected prostheses, correlating its results with medical workup, echo-
cardiogram and dedicated CT.
Patients: Fourteen patients (pts) with cardiovascular prostheses (seven with
a pacemaker, four with vascular grafts, two with pulmonary stent and one with
mitral valve prosthesis were hospitalized for prolonged fever.
Methods: All pts received antibiotics and underwent repeated medical
workup. Eight of the 14 pts had a proven bacteriemia. Transthoracic and tran-
soesophagial echocardiogram was performed as well as CT, for most of them.
FDG PET-CT was performed in all of them, following injection of 370 MBq
of F-18 FDG. All patients were normoglycemic at the time of injection.
Results of the FDG PET-CT were compared with other diagnostic modalities
and clinical follow up.
Results: In the 7 pts with pacemaker, FDG PET-CT was positive in 4,
echo in 2/4. IN 3/4 the device was removed. A new pacemaker was
implanted for two patients after few weeks. FEG PET-CT was negative in
3/7 pts with 1 positive, 1 negative and 1 intermediate results. All patients
with vascular graft had positive FDG PET-CT scan and only one had a
positive echocardiogram. This patient had a surgical proven abscess. Two
pts with pulmonary stent had a positive FDG PET-CT scan and 1 positive
echo. In this patient the stent extracted was infected. FDG PET-CT and
echo was negative in the patient with mitral prosthesis.Conventional CT
was positive in only 1 patient. Twelve pts return to normal including all
the patients after prostheses extraction except one who died during graft
replacement.
Conclusion: FDG PET -CT is a useful tool for the diagnosis of infected
cardiovascular prosthesis and is more accurate than stand alone CT. Correla-
tion of the clinical, echo and FDG PET CT findings is crucial for the thera-
peutic decision. 
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Introduction: The emergence of new herapies based on enhanced pre-
vention and treatment of viral diseases led to a significant improvement in
hemophiliacs’ life expectancy. Consequently, they are currently exposed to
cardiovascular diseases and candidates for antithrombotic treatments. The
benefits of antithrombotic therapy have not been demonstrated for this pop-
ulation and abnormal blood crasis may also provide a degree of antithrom-
botic protection. In this study, we aim to assess the prevalence of
cardiovascular disease and cardiovascular risk factors in patients with
hemophilia, but also collect data concerning the management of these dis-
eases. 
Methods: This study prospective, observational and monocentric was con-
ducted in a cohort of patients over 50 year old hemophiliacs followed at the
Regional Center for Hemophilia Midi Pyrénées. Patients were considered eli-
gible if their cardiovascular risk was moderate to high according to the
SCORE scale. A cardiovascular screening was performed including assess-
ment of risk factors and detection of peripheral and coronary atheromatous
plaque.
Results: 45 patients were enrolled from december 2010 to january 2013,
including 22 with minor hemophilia; 15 with moderate hemophilia; and 8
severe hemophiliacs. Monitoring was conducted until January 2014. 47% of
the patients (10 patients) had a very high cardiovascular risk. For 21 patients
(46.7%), the screening led to change cardiovascular medications or to propose
invasive treatment. Anti thrombotic treatment was prescribed to 11 patients.
3 patients were treated with double platelet anti-aggregation; 7 with single
platelet anti-aggregation and 1 patient with Vitamine K antagonists. No major
bleedings were reported. 
Conclusion: The prevalence of cardiovascular risk factors and of cardio-
vascular disease in patients with hemophilia is not negligible. Based on a per-
sonalized approach, antithrombotic therapies might be prescribed without
major bleeding complications. 
